유방암 생존자와 중년여성의 갱년기 증상 및 인지기능 비교
Comparison of Climacteric Symptoms and Cognitive Impairment in Breast Cancer Survivors and Healthy Women
0
조회
0
다운로드
9
인용
0
참고문헌
키워드
초록
Purpose: This study was to compare climacteric symptoms and cognitive impairment in breast cancer survivors (n=51) and healthy women (n=51). Methods: This study was conducted from January 4th, 2012 to February 16th, 2012. We individually matched healthy women to breast cancer survivors based on age and education, and assessed a questionnaire regarding climacteric symptoms and cognitive impairment. Data were analyzed by using χ2, t-test, and Pearson correlation with the SPSS/Win 12.0 program. Results: The average score for the climacteric symptoms (19.71) was significantly different (t=-2.78, p=.006) to the average for the breast cancer survivors (15.53). The average cognitive impairment score for the breast cancer survivors (86.37) was significantly different (t=-2.45,p=.016) to the average score for the healthy women (67.92). The climacteric symptoms score showed a significant relationship with cognitive impairment. Conclusion: These results support that adjuvant chemotherapy and anti-hormone therapy are associated with climacteric symptoms and adverse cognitive effects in breast cancer survivors.
Abstract
Purpose: This study was to compare climacteric symptoms and cognitive impairment in breast cancer survivors (n=51) and healthy women (n=51). Methods: This study was conducted from January 4th, 2012 to February 16th, 2012. We individually matched healthy women to breast cancer survivors based on age and education, and assessed a questionnaire regarding climacteric symptoms and cognitive impairment. Data were analyzed by using χ2, t-test, and Pearson correlation with the SPSS/Win 12.0 program. Results: The average score for the climacteric symptoms (19.71) was significantly different (t=-2.78, p=.006) to the average for the breast cancer survivors (15.53). The average cognitive impairment score for the breast cancer survivors (86.37) was significantly different (t=-2.45,p=.016) to the average score for the healthy women (67.92). The climacteric symptoms score showed a significant relationship with cognitive impairment. Conclusion: These results support that adjuvant chemotherapy and anti-hormone therapy are associated with climacteric symptoms and adverse cognitive effects in breast cancer survivors.
참고문헌 (30)
- Hess LM, "Chemotherapy related change in cognitive function : A conceptual model", Oncol Nurs Forum, 34, pp.971~980 (2007)
- Brem S, "Management of treatment-related symptoms in patients with breast cancer : Current strategies and future directions", Clin J Oncol Nurs, 15, pp.63~71 (2011)
- Biglia N, "Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight", J Sex Med, 7, pp.1891~1900 (2010)
- Mols F, "Quality of life among long-term breast cancer survivors : A systematic review", Eur J Cancer, 41, pp.2613~2619 (2005)
- Vearncombe KJ, "Predictors of cognitive decline after chemotherapy in breast cancer patients", J Int Neuropsychol Soc, 15, pp.951~962 (2009)
- Weiss B, "Evaluation of multiple neurotoxic outcomes in cancer chemotherapy", Adv Exp Med Biol, 678, pp.96~112 (2010)
- Biegler KA, "Cancer, cognitive impairment, and mediation", Acta Oncol, 48, pp.18~26 (2009)
- Ah DV, "Cognitive dysfunction and it’s relationship to quality of life in breast cancer survivors", Oncol Nurs Forum, 36, pp.326~334 (2009)
- Moon JM, "Menopause symptoms, fatigue, and quality of life in post-chemotherapy breast cancer survivors", pp.2009
- Jansen CE, "Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide", Psycho-oncology, 17, pp.1189~1195 (2008)
- Vardy J, "Cognitive function in breast cancer survivors", Cancer Treat Res, 151, pp.1451~1467 (2009)
- Bender CM, "Cognitive impairment associated with adjuvant therapy in women with breast cancer", Psycho-oncology, 15, pp.422~430 (2006)
- Hermelink K, "Cognitive function during neoadjuvant chemotherapy for breast cancer : Results of a prospective, multicenter, longitudinal study", Cancer, 109, pp.1905~1913 (2007)
- Nelson CJ, "Chemotherapy and cognitive deficit : Mechanisms, findings, and potential interventions", Palliat Support Care, 5, pp.273~280 (2007)
- Jenkins V, "A 3-year prospective study of the effects of adjuvant treatment on cognition in women with early stage breast cancer", Br J Cancer, 94, pp.828~834 (2006)
- Calvio L, "Measures of cognitive function and work in occupationally active breast cancer survivors", J Occup Environ Med, 52, pp.219~227 (2010)
- Schilling V, "Self reported cognitive problems in women receiving adjuvant therapy for breast cancer", Eur J Oncol Nurs, 11, pp.6~15 (2007)
- Catherine EJ, "A metaanalysis of the sensitivity of various neuropsychological test used to detect chemotherapy induced cognitive impairment in patients with breast cancer", Oncol Nurs Forum, 34, pp.997~1005 (2007)
- Phillips KA, "Do aromatase inhibitors have adverse effects on cognitive function?", Breast Cancer Res, 13, pp.203~ (2011)
- Falleti MG, "The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women breast cancer : A meta-analysis of the current literature", Brain Cogn, 59, pp.60~70 (2005)
- Wefel JS, "Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer", Cancer, 116, pp.3348~3356 (2010)
- Jo HS, "A comparative study on climacteric symptoms of natural menopausal women and artificial menopausal women", J Korean Acad Nurs, 31, pp.692~700 (2001)
- Development of the cognitive function scale for breast cancer patients, "Chung BY", Ministry of Education, Science and Technology, ~ (2011)
- Carpente JS, "Hot flashes and related outcomes in breast cancer survivors and matched comparison women", Oncol Nurs Forum, 29, pp.16~25 (2002)
- Crandall C, "Association of breast cancer and it’s therapy with menopause-related symptoms", Menopause, 11, pp.519~530 (2004)
- Lejbak L, "Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive task in postmenopausal women with breast cancer", J Clin Exp Neuropsychol, 32, pp.836~846 (2010)
- Ganz PA, "Breast cancer, menopause, and long term survivorship : Clitical issue for the 21st century", Am J Med, 118, pp.1365~1415 (2005)
- Yun MR, "Menopausal symptoms and menstrual changes in breast cancer survivors treated with adjuvant chemotherapy", pp.2004
- Silverman DHS, "Cognitive dysfunction associated with chemotherapy for breast cancer", Future Neurol, 2, pp.271~277 (2007)
- Victor WH, "Cognitive changes after menopause : Influence of estrogen", Clin Obstet Gynecol, 51, pp.618~626 (2008)